Method of treating restenosis using bisphosphonate nanoparticles

US6984400B2 · kind B2 · utility

Assignee

• YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. · IL

Inventors

• Gershon Golomb · Beer Sheva, IL
• Haim Danenberg · Mevaseret Tsiyon, IL

Key dates

• Filing date: Apr 19, 2002
• Grant date: Jan 10, 2006
• Expiry date: May 8, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K33/24
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient. The active ingredient effects restenosis by inhibiting the growth and proliferation of the cell types involved in the restenotic cascade, such as macrophages/monocytes, fibroblasts and smooth-muscle cells.